Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Market News
ASX 200 up 0.5%: CSL signs COVID-19 vaccine agreements, big four banks charge higher
Share Fallers
Why Afterpay, ASX, Mesoblast, & Sydney Airport shares are dropping lower
Share Market News
Why the Mesoblast share price jumped higher this morning
Share Gainers
Why Brainchip, De Grey, Mesoblast, & SKYCITY shares are pushing higher
Share Gainers
The Mesoblast share price rocketed 40% higher in August: Is it too late to invest?
Share Market News
Mesoblast share price flat on Australian phase 3 COVID-19 trial news
Share Gainers
These were the best performing ASX 200 shares in August
Healthcare Shares
Up 38% in August, is the Mesoblast share price a buy?
Share Market News
Bulls versus bears – two experts face off on where share prices are going
Healthcare Shares
Mesoblast share price on the rise after delivering promising FY20 results
Share Market News
Hydrix and Zip were among the most traded shares on the ASX last week
⏸️ International Shares
How to boost your share market gains
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
